CS
RNAC icon

Credit Suisse’s Cartesian Therapeutics RNAC Stock Holding History

Credit Suisse’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-389
Closed -$37K – 4197
2021
Q4 		$37K Buy
+389
New +$41.9K ﹤0.01% 4435
2021
Q1 		– Sell
-685
Closed -$62K – 4514
2020
Q4 		$62K Buy
+685
New +$59.4K ﹤0.01% 4230
2017
Q4 		– Sell
-376
Closed -$205K – 4176
2017
Q3 		$205K Buy
+376
New +$200K ﹤0.01% 3919

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
N
NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's RNAC Position: Q1 2022 in Review

Credit Suisse sold out of Cartesian Therapeutics (RNAC) in Q1 2022, closing a stake of 389 shares — an estimated $37K sold.

Credit Suisse first reported a position in RNAC in Q3 2017 and held it in 3 quarters. The position peaked at $205K in Q3 2017. 102 funds tracked by Wall St. Rank hold RNAC as of Q1 2022.

  • Credit Suisse reported no remaining Cartesian Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Credit Suisse sold 389 Cartesian Therapeutics shares in Q1 2022, an estimated $37K.
  • Credit Suisse first reported a position in Cartesian Therapeutics in Q3 2017 and held it in 3 quarters.
  • Credit Suisse's Cartesian Therapeutics position peaked at $205K in Q3 2017.
  • 102 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2022.

Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.